A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases

Clinical trial NCT06926803 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06926803
Sponsor: Qiming Wang
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL

Lung Cancer (NSCLC)Leptomeningeal Cancer

Start date: 2025-03-01
Primary completion: 2025-06-30
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.